A stable cocarboxylase arginate is prepared by reacting one mole of cocarboxylase with at least one mole of arginine or a salt thereof. The cocarboxylase arginate product may be recovered from the reaction mixture by conventional techniques, and has excellent moisture stability and an enhanced pharmaceutical activity.

The invention provides compounds of formula I, wherein R.sup.1 represents the non-hydroxy portion of a triazole antifungal compound of the type comprising a tertiary hydroxy group; or a pharmaceutically acceptable salt thereof. The compounds of the invention are useful in the treatment of fungal infections, and have good aqueous solubility.

The invention relates to a method for removing phosphoric acid, thiamine triphosphate and higher thiamine phosphates from solutions that contain phosphoric acid, thiamine monophosphate, thiamine diphosphate, diamine triphosphate and higher phosphates. The inventive method is characterized by passing the phosphoric acid solution of thiamine phosphates over a non-ionogenic adsorber resin which comprises unsaturated cyclic nitrogen bases and eluting thiamine monophosphate and thiamine diphosphate w...

A cyclic nucleotide phosphonate ester characterized by the presence of an n-butyl salicylate ester group linked to the phosphorus atom of cHPMPC is disclosed. The analog comprises an ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog.

Nucleotide analogues having the general formula (I) and pharmaceutically acceptable derivatives: ##STR1## wherein n is 0 or an integer; X is O or S, CH.sub.2, CH-halogen, CH--N.sub.3, or C.dbd.CH.sub.2 ; Q and U are independently selected from: O, S, and CH(R.sub.a) wherein R.sub.a is hydrogen, OH, halogen, N.sub.3, NH.sub.2, SH, carboxyl, C.sub.1-6 alkyl or R.sub.a is CH.sub.2 (R.sub.b) wherein R.sub.b is hydrogen, OH, SH, NH.sub.2, C.sub.1-6 alkyl or carboxyl; or both Q and U are CH when Q and...

An improved process for the production of Diazinon substantially free of toxic by-products in high yield and very high purity which involves mixing 2-isopropyl-4-methyl-6-hydroxypyrimidine with solid sodium or potassium hydroxide in a ketone or ether solvent at a temperature of about 50.degree.-60.degree. C. until a homogeneous mixture is formed, adding diethylthiophosphoryl chloride to the homogeneous mixture, keeping the mixture at a temperature of 55.degree.-80.degree. C. until the reaction i...

New derivatives of pyrazolo[1,5-a]pyrido[3,2-e]-pyrimidine-7-carboxylic acid have the general formula ##STR1## The new compounds are useful as central nervous system depressants and as anti-inflammatory agents.

Provided are compounds of the following formulae: A phosphonomethoxymethyoxymethyl purine/pyrimidine derivative of the formula ##STR1## wherein X and X' are the same or different and are hydrogen or alkyl. R and R' are the same or different and are hydrogen, alkyl, hydroyalkyl or alkanoyl and B is a purine or pyrimidine base. A compound of formula (II) or (VIII) ##STR2## wherein the broken line is an optional bond; X, R and X' are the same or different and are H or alkyl with 1 to 6 carbon atoms...

N-[5-(Diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2- yl]-N-methylmethanesulfonamide of the formula: ##STR1## is prepared by reaction of [4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidi n-5-yl]methanol with chlorodiphenylphosphine. Compound I is an intermediate in the synthesis of pharmaceutically active compounds, in particular HMG--Co A. reductase inhibitors.

Disclosed are novel prodrugs represented by the following structural formula: ##STR1## Z is oxygen or sulfur; Y is, together with a hydroxy group, acyclovir or an analog of acyclovir; A is a substituted benzyl group with one or more protected hydroxy or protected amine groups in the ortho or para positions, relative to the phosphate ester, which can be converted in vivo to a hydroxy or amino group. Also disclosed is a method of treating a viral infection in an individual or animal. The method co...